Abstract: An assay to determine anticoagulants in a blood or blood plasma sample, wherein the assay comprises analyses with at least two wet chemistry prothrombine time (PT) methods. The assay comprises measuring PT in a first reaction mixture with a first PT method and measuring PT in a second reaction mixture with a second PT method, wherein the concentration of blood or blood plasma in the second reaction mixture differs from the concentration of blood or blood plasma in the first reaction mixture. The PT methods are calibrated to give the same or approximately the same PT results for reference samples which lack anticoagulants of interest for the assay. Further, calculating a difference in PT from the measurements, wherein if the difference in PT is 1) significant, this is indicative of a presence of anticoagulants in the sample, or 2) non-significant, this is indicative of an absence of anti-coagulants above detectable level in the sample.

Abstract: A system for enabling test data resulting from an analytic determination carried out on a clinical analytic device (20-1) to be communicated to an electronic patient information management system (80), the system comprising: a computer module (120-1) communicatively connectable to the clinical analytic device (20-1), a user operable control unit (140) communicatively connectable to the computer module (120-1), and an instrument tag (22-1) readable by the user operable control unit (140) and associated with the clinical analytic device (20-1).

Abstract: An assay to determine anticoagulants in a blood or blood plasma sample, wherein the assay comprises analyses with at least two wet chemistry prothrombine time (PT) methods. The assay comprises measuring PT in a first reaction mixture with a first PT method and measuring PT in a second reaction mixture with a second PT method, wherein the concentration of blood or blood plasma in the second reaction mixture differs from the concentration of blood or blood plasma in the first reaction mixture. The PT methods are calibrated to give the same or approximately the same PT results for reference samples which lack anticoagulants of interest for the assay. Further, calculating a difference in PT from the measurements, wherein if the difference in PT is 1) significant, this is indicative of a presence of anticoagulants in the sample, or 2) non-significant, this is indicative of an absence of anti-coagulants above detectable level in the sample.

Abstract: A method to determine an analyte concentration of an anticoagulated plasma by performing at least two different measurements on a mixture of a blood sample corresponding to said anticoagulant plasma and of liquid reagent is described. The method comprises a) mixing a volume of said blood sample with a five-fold, or more, volume of said liquid reagent, b) performing said at least two measurements on said mixture, at least one of which correlates with the hematocrit of said blood sample and at least one of which correlates with said analyte concentration, and c) computing the results from the measurements when the volumes in a) are precise and accurate or when the hematocrit of said blood sample in b) is known to determine said analyte concentration of said anticoagulated plasma. In addition, a measurement and determination device for performing measurements on blood, anticoagulated blood and/or anticoagulated plasma samples, and an equipment kit are described.

Abstract: A system for enabling test data resulting from an analytic determination carried out on a clinical analytic device (20-1) to be communicated to an electronic patient information management system (80), the system comprising: a computer module (120-1) communicatively connectable to the clinical analytic device (20-1), a user operable control unit (140) communicatively connectable to the computer module (120-1), and an instrument tag (22-1) readable by the user operable control unit (140) and associated with the clinical analytic device (20-1).

Abstract: A surface plasmon apparatus includes a light source, a sensor unit for Surface Plasmon Resonance (SPR) which includes a transparent sensor structure forming at least one wall of a cavity, the wall being defined by a concave inner surface and a convex outer surface, wherein the inner surface is provided with a layer of a conductive material capable of supporting a surface plasmon, a flow structure in the cavity so as to form at least one compartment for sample between the flow structure and the inner wall of the cavity, a detector for detecting reflected light from the sensor unit, and a processing unit.

Abstract: A surface plasmon apparatus includes a light source, a sensor unit for Surface Plasmon Resonance (SPR) which includes a transparent sensor structure forming at least one wall of a cavity, the wall being defined by a concave inner surface and a convex outer surface, wherein the inner surface is provided with a layer of a conductive material capable of supporting a surface plasmon, a flow structure in the cavity so as to form at least one compartment for sample between the flow structure and the inner wall of the cavity, a detector for detecting reflected light from the sensor unit, and a processing unit.

Abstract: The invention relates to a sensor unit for a Surface Plasmon Resonance (SPR) unit, comprising a transparent sensor structure forming at least one wall of a cavity, the wall being defined by a concave inner surface and a convex outer surface The inner surface is provided with a layer of a conductive material capable of supporting a surface plasmon. In the cavity there is provided a flow structure in said cavity so as to form at least one compartment for sample between the flow structure and the inner wall of the cavity. Also, a method for the detection of events at a surface by utilizing surface plasmon resonance is provided. It comprises placing a sample with an analyte of interest in a sensor unit as claimed in claim 1, and measuring the reflectance from said sensor unit at a single or plurality of angle/angles.

Abstract: The invention relates to a sensor unit for a Surface Plasmon Resonance (SPR) unit, comprising a transparent sensor structure forming at least one wall of a cavity, the wall being defined by a concave inner surface and a convex outer surface The inner surface is provided with a layer of a conductive material capable of supporting a surface plasmon. In the cavity there is provided a flow structure in said cavity so as to form at least one compartment for sample between the flow structure and the inner wall of the cavity. Also, a method for the detection of events at a surface by utilizing surface plasmon resonance is provided. It comprises placing a sample with an analyte of interest in a sensor unit as claimed in claim 1, and measuring the reflectance from said sensor unit at a single or plurality of angle/angles.

Abstract: A method to determine an analyte concentration of an anticoagulated plasma by performing at least two different measurements on a mixture of a blood sample corresponding to said anticoagulant plasma and of liquid reagent is described. The method comprises a) mixing a volume of said blood sample with a five-fold, or more, volume of said liquid reagent, b) performing said at least two measurements on said mixture, at least one of which correlates with the hematocrit of said blood sample and at least one of which correlates with said analyte concentration, and c) computing the results from the measurements when the volumes in a) are precise and accurate or when the hematocrit of said blood sample in b) is known to determine said analyte concentration of said anticoagulated plasma. In addition, a measurement and determination device for performing measurements on blood, anticoagulated blood and/or anticoagulated plasma samples, and an equipment kit are described.

Abstract: A method of determining prothrombin time (PT) in a whole blood, anti-coagulated blood, blood plasma or anti-coagulated blood plasma sample at an ambient temperature in the range of 15° C. to 45° C. is described. The method is performed with liquid reagents and the PT, preferably expressed as International Normalized Ratio (INR), is calculated based on said temperature and the clotting time (CT). A test kit is also described for analysis of PT which comprises temperature recoding means, and one or several separate sealed vessels containing reagents, optionally in lyophilized form for reconstitution prior to use, for clotting one or more defined volumes of whole blood, anti-coagulated blood, blood plasma or anti-coagulated blood plasma sample, and optionally time registration means and volume determining means.

Abstract: The invention relates to a pharmaceutical composition to be applied superficially, whereby the pharmaceutical composition comprises erythropoietin (EPO) and a pharmaceutically acceptable diluent, adjuvant, or carrier.

Abstract: An active ingredient for producing a medicament for inhibiting the coagulation of blood, and a corresponding medicament are provided. The active ingredient is isocitrate or an active derivative thereof.

Abstract: A method of anti-coagulating a blood, blood plasma or synovial fluid product comprising addition to the product iso-citrate is described. The method may further comprise adjustment of the calcium ion activity of the anti-coagulated product to physiological levels with a soluble calcium salt. Blood, blood plasma or synovial fluid products containing an anti-coagulating amount of anti-coagulant comprising iso-citrate, and optionally citrate, is disclosed. These anti-coagulated products are used for transport and storage of the products and/or for analysis of hemostatic or coagulative properties of the products. Additionally, blood sampling containers comprising isotonic or slightly hypertonic solutions of iso-citrate, and blood sampling containers comprising a solution of 0.1-0.5 M iso-citrate in one tenth of the container volume, and optionally an effective amount of calcium chloride resulting in a calcium ion activity of approximately 1 mM, are disclosed.